EOLS - NASDAQ
Evolus, Inc.
$6.03
-2.3%Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
At a Glance
Live Snapshoteols
Additional Paid-In Capital
Last Annual Value
638.09M
3-Year CAGR
7%
5-Year CAGR
16%
10-Year CAGR
27%
Evolus, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Evolus, Inc. NASDAQ:EOLS | 638.09M | 5.8% | 4.8% | 26.7% | |
 Neurogene Inc. NASDAQ:NGNE | 0.00 | N/A | N/A | N/A | |
 Treace Medical Concepts, Inc. NASDAQ:TMCI | 0.00 | N/A | N/A | N/A | |
 CeriBell, Inc. NASDAQ:CBLL | 375.50M | 197.7% | N/A | N/A | |
 Quantum-Si incorporated NASDAQ:QSI | 918.19M | 6.2% | 4.3% | N/A | |
 Enhabit, Inc. NYSE:EHAB | 443.60M | 2.2% | -16.5% | N/A | |
 Solid Biosciences Inc. NASDAQ:SLDB | 1.14B | 13.2% | 10.7% | 114.3% | |
 OrthoPediatrics Corp. NASDAQ:KIDS | 622.33M | 2.4% | 9.5% | 47.4% | |
 The Oncology Institute, Inc. NASDAQ:TOI | 256.71M | 7.9% | 8.9% | N/A |
Evolus, Inc. Fair Value Envelope
Related Guides
Continue your EOLS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.